FOXP3 and neoplasm: Finally, using IHC we found significant decrease in the number of FOXP3 expressing cells in all the Foxp3-ASO treatment arms in both the tumour and the spleen (Fig. 7D, E, Supplementary Fig. S8G, S8H) and an increase in TBET expressing cells in the tumour (Fig. 7E).